Facts of Imbruvica (Ibrutinib)Capsules ?
- Medicine Name: Imbruvica
- Date of Approval: 13.11.2013
- Company Name: Janssen Biotech, Inc.
IMBRUVICA® is a prescription medicine used to treat people with:
For MCL IMBRUVICA® is approved on response. Data are not yet available to show if IMBRUVICA® improves survival or symptoms
The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) capsules for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA for a condition for which it was not prescribed. Do not give IMBRUVICA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA that is written for health professionals.
It is not known if IMBRUVICA® is safe and effective in children.